Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) rose 0.6% on Wednesday . The stock traded as high as $1.81 and last traded at $1.80. Approximately 3,057 shares changed hands during trading, a decline of 65% from the average session volume of 8,795 shares. The stock had previously closed at $1.79.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Innate Pharma in a research report on Tuesday, April 7th. Weiss Ratings raised shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Innate Pharma has an average rating of “Moderate Buy” and a consensus price target of $5.00.
Check Out Our Latest Stock Analysis on Innate Pharma
Innate Pharma Price Performance
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in Innate Pharma during the 4th quarter valued at $36,000. OLD Mission Capital LLC bought a new position in shares of Innate Pharma during the 4th quarter worth $50,000. Finally, Jane Street Group LLC purchased a new position in shares of Innate Pharma during the fourth quarter valued at $162,000. 0.16% of the stock is currently owned by hedge funds and other institutional investors.
Innate Pharma Company Profile
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.
Further Reading
- Five stocks we like better than Innate Pharma
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
